Invasive coronary angiography is known for its precision in delineating topographical anatomy of lumen of epicardial coronary arteries, but lacks the ability to determine the functional significance of coronary stenoses. Functional severity of coronary narrowing has been determined to be the most prominent prognostic [ 2 0 _ T D $ D I F F ] factor among the individuals with documented coronary artery disease. 1 Hence, combined assessment of anatomy and functional information with high accuracy would help in guiding the treatment strategy for patients with known or suspected coronary artery disease, particularly those with intermediate degree of stenosis. 2 It is derived from the ratio between coronary (distal to stenosis) and aortic pressure measurements during maximal hyperemia. 3 Hence FFR in combination with conventional angiography is rapidly emerging as an accurate approach of combining anatomy and physiology.
Role of FFR in determining the need for coronary stenting has been studied in various trials and has been recommended to assess the significance of intermediate coronary lesions 2, 3, [5] [6] [7] . FFR has been demonstrated to be an useful index in patients referred for percutaneous revascularisation [ In this study, we intended to assess the clinical outcome of FFR-based management strategies in Indian patients, the results of which could serve to validate and re-emphasize the utility of this investigation in our setting. 
Study patients
Medical records of all patients who underwent FFR during the period between June 2010 to June 2015 were reviewed.
Inclusion criteria
All patients with stable ischemic heart disease with denovo intermediate lesions or those patients who had acute coronary event a week or more prior to the procedure 
Quantitative coronary arteriography
Angiograms were reviewed by two independent investigators to determine the severity. Quantitative assessment of lesions (QCA À Quantitative Coronary Angiography) was done using a validated software employing Siemens/Philips algorithm. 
Primary end point
The primary endpoint during the follow-up was major adverse cardiac events (MACE), defined as composite of cardiovascular death, non-fatal acute coronary syndrome, and any repeat revascularization of the vessel in which FFR was studied (target vessel revascularization -TVR). A repeat angiogram was performed only when indicated clinically. The culprit artery responsible for the recurrence of symptoms was based on the correlation of electrocardiographic changes, echocardiographic data (if available), and the diagnostic angiogram.
Secondary end point
The secondary endpoints were individual components of the MACE. Myocardial infarction was defined as (two out of three criteria): prolonged chest pain >20 min; levels of serum creatine kinase (or the MB fraction) or troponin over two-fold higher than the upper normal limit; and ST-T segment changes or new Q waves on serial electrocardiogram indicative of myocardial damage.
Statistical analysis
The data was Table 1. 281 (99.6%) patients had regular follow up in our interventional clinic at 3 weeks, 3 months, 6 months, 1 year after the procedure and thereafter yearly. One patient was lost to followup in group 1. (Fig. 1) . Event Àfree survival analysis over the followup period by Kaplan Àmeier method showed no statistically significant difference (p = 0.73) between the medical group (group 1) and revascularised group (group 2). Since non-revascularised group (group 3) was underpowered, statistical significance [ 5 2 _ T D $ D I F F ] of event free survival of this group in comparison with other groups was not considered (Fig. 2), (Table 2 ).
Discussion
In this study, we compared the clinical outcomes of FFR assessment In our retrospective study, we found a higher prevalence of patients with positive FFR (68.1%). In the DEFER study, where enrollment was based primarily on angiographic assessment of patients with negative stress test or without a stress test, the prevalence of positive FFR was about 55%. 3 However, in the allcomers FAME-2 study, which included consecutive patients who underwent angiography for their symptoms and were found to have at least 50% stenosis in coronary angiogram, 72% of the 1220 patients who were eligible were found to have FFR < 0.8. This is similar to what was found in our study, where the patients underwent angiogram for clinical indications, with about 60% of the entire study population having had a positive or inconclusive stress test prior to angiography. The angiographic severity of the lesion was assessed using quantitative coronary angiography (QCA) algorithms, and it has been reported that QCA algorithms often yield lesser stenotic severity when compared to visual assessment. 20 This too would have contributed to higher FFR positivity rates, unlike studies which mainly employed visual assessment for severity estimation of lesions.
The clinical outcomes in patients who were kept on medical management after negative FFR result were comparable to other studies. In DEFER trial, 3, 7 which randomised patients with FFR ! 0.75 into deferred group and PCI group showed that the 5-year event-free survival rates were statistically comparable Many other smaller studies [23] [24] [25] [26] [27] [28] [29] similarly have demonstrated consistently low rates of death and myocardial infarction in patients with deferred treatment of lesions. Those patients who were advised revascularization based on the FFR values and underwent the procedure in our study (group 2) had MACE rate of 2.3% over 18 months. In the FAME-2 trial, the MACE rate was 4.3% at one year in patients who underwent PCI. [ 6 0 _ T D $ D I F F ] Our patients were younger (mean age of 56.3 years vs 63.5 years in FAME 2) and had fewer acute coronary events before angiography (12% vs 37%). The definition of MACE in our study (cardiovascular death, non fatal ACS, target vessel revascularization) [ 6 1 _ T D $ D I F F ] and in FAME 2 (any death, non fatal MI, any repeat revascularization) was also different. While the mode of revascularization was only PCI in FAME 2, our patients underwent either PCI or CABG. These factors along with the shorter duration of follow up might have contributed to the apparent difference in the primary end point rates between the two studies.
There was [ 6 2 _ T D $ D I F F ] remarkable difference in the MACE rates between patients who underwent revascularization and those who refused it initially (2.3%vs 41.17%) in our study than what was reported in the FAME 2 trial (4.3% in the PCI group vs 12.7% in the group with FFR 0.8 randomised to medical management). This appears to be driven by a high rate of events in the group of patients who refused revascularization initially in our study. The higher event rates could be explained by higher risk profile (Diabetes 41.2% -vs 25%), more patients with extensive coronary involvement (Multivessel disease 100% vs 22.3%), more symptomatic patients [ 6 3 _ T D $ D I F F ] (NYHA FC III/IV symptoms 41.2% vs 22.5%) in our study compared to FAME 2 trial.
To the best of our knowledge, this is the first Indian study of its nature. Despite the differences in clinical profile of patients when compared with those in randomised clinical trials, the data from this study which reflects real-world practice, helps in reassuring the utility of FFR-based clinical decisions in patients with CAD in this part of the world. Though, not an objective of the study, we noted that size of coronaries in our study population were comparable to those enrolled in major randomised trials like FAME and DEFER, which is unlike the preexisting notion of smaller coronaries in Asians/Indians. (Mean reference vessel diameter measured by QCA was 3.1 AE 0.7 mm in our study population compared to 2.5 AE 0.7 mm in FAME and 3.0 AE 0.6 mm in DEFER).
Limitations
The study, being a retrospective and non-randomised one, limits comparison of competing strategies.The smaller sample size in the third group might have inflated the event rates.Since diabetic patients are of significant proportion, assessment of microvascular status by IMR/HMR might have added to overall assessment.
Conclusion
Among patients with intermediate coronary [ 6 4 _ T D $ D I F F ] artery disease having at least one stenosis with an FFR of 0.80, FFR-guided revascularization (PCI with drug eluting stents or CABG) plus medical therapy, had similar rates of mortality, MI and need for urgent revascularization, as compared with the patients with FFR of > 0.8 on medical therapy alone.
This study also highlights the importance of timely revascularisation in patients with ischemic FFR, as emphasized by higher MACE rate of 41% among the patients with FFR of 0.80 or less but did not undergo revascularisation.
Thus, we conclude that in our retrospective study, FFR based clinical decisions in the management of patients with coronary artery disease was safe [ ( F i g . _ 2 ) T D $ F I G ] 
